No Data
No Data
Beijing SL Pharmaceutical (002038.SZ): obtained the registration certificate for the pharmaceutical injection of Leuprorelin.
On October 15th, Beijing SL Pharmaceutical (002038.SZ) announced that the company recently received the approval and issuance of the registration certificate of the pharmaceutical Eptifibatide Injection (trade name: Yiven) (10ml:20mg) by the National Medical Products Administration. Eptifibatide is a specific platelet glycoprotein IIb/IIIa receptor antagonist that reverses the ischemic state caused by thrombus formation by selectively and reversibly inhibiting the final common pathway of platelet aggregation. It is mainly used clinically for post-intervention anti-thrombotic treatment in patients with acute coronary syndrome, and can also be used in non-atherosclerotic vascular diseases.
Beijing Sl Pharmaceutical: Half-year report for the year 2024.
Beijing Sl Pharmaceutical: Summary of Half-Year Report in 2024.
Beijing Sl Pharmaceutical: Beijing SL Pharmaceutical Co., Ltd. announces its performance forecast for the first half of 2024.
Beijing SL Pharmaceutical (002038.SZ) issued a profit warning, expecting a net income of 28 million yuan to 42 million yuan in the first half of the year, a decrease of 86.76% to 91.17%.
Beijing SL Pharmaceutical (002038.SZ) released its performance forecast for the first half of 2024, expecting a net income of 28 million yuan to 42 million yuan attributable to shareholders of the listed company, a year-on-year decrease of 86.76% to 91.17%. During the reporting period, the net income attributable to shareholders of the listed company decreased significantly compared with the same period of the previous year, mainly due to the fair value change of trading financial assets and available-for-sale financial assets in non-recurring gains and losses during this reporting period. The fair value change gains and losses for January-June 2023 were 0.108 billion yuan, and for January-June 2024
Beijing SL Pharmaceutical (002038.SZ) has obtained the registration certificate for pharmaceutical of ammonium sulfate glucosamine capsule.
Beijing SL Pharmaceutical (002038.SZ) announced that it has recently received the Drug Registration Certificate for aminoacridine sulfate capsules (trade name: Jining) issued and approved by the National Medical Products Administration (NMPA). Aminoacridine is a naturally occurring monosaccharide in human physiological state and is an essential substance for the synthesis of proteoglycans in human joint cartilage matrix. It can stimulate chondrocytes to produce polysaccharides with normal polymeric structure, improve the repair ability of chondrocytes, inhibit enzymes that damage cartilage (such as collagenases and phospholipase A2), and prevent damage to cells from excessive.
No Data
No Data